[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":-5,"_23":24,"_25":26,"_27":28,"_29":30,"_31":30,"_32":33,"_34":35,"_36":37,"_38":39,"_40":41,"_42":43,"_44":45,"_46":-5,"_47":48,"_49":-5,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":41,"_58":41,"_59":60,"_61":41,"_62":63},"id","gv83tere3h9ug7v32ezu06dv3","revision",2,"title","Wave Life Sciences 提交 8-K，披露 2026 财年第三季度业绩公告","originalTitle","8-K - Wave Life Sciences, Inc. (0001631574) (Filer)","summary","Wave Life Sciences 于 2026 年 10 月 27 日提交 Form 8-K，宣布截至 2026 年 9 月 30 日季度的财务业绩。相关业绩新闻稿作为附件 99.1 随文件提供；该信息标注为“提供”而非正式“提交”。","reason","source",{"_12":86,"_87":88,"_9":89,"_90":41,"_91":92,"_93":94},"links",{"_83":84,"_76":85},"publishedAt","2026-10-27T11:35:46.000Z","discoveredAt","2026-10-27T11:37:52.344Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",26,"selected",true,"channel","news","story",{"_71":72,"_16":73},"x","readingMode","full","author","language","body",{"_63":75,"_76":-5,"_77":78,"_79":41},"outline",[],"relatedStories",[74],"indexable","markdownAvailable","group",{"_64":65,"_44":66,"_67":15,"_68":69,"_70":69},"hasTranslation","bodyLanguage","zh","factId","fjT74Ym_6REk",{"_71":72,"_16":73},"reportCount","additionalSourceCount",1,"developmentCount","publicId","36b3eed3-3a16-4bf3-8d61-2506b8f8d77b","Wave Life Sciences公布第三季度业绩并推进WVE-006开发",{"_71":72,"_16":73},"

美国

证券交易委员会

华盛顿特区 20549

Form 8-K

当前报告

根据《1934年证券交易法》第13或15(d)条

《1934年证券交易法》

报告日期（最早报告事件日期）：2026年10月27日

WAVE LIFE SCIENCES, INC.

（注册人章程中规定的确切名称）

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n	\n	\n
特拉华州		001-37627		42-2115035
（注册成立所在州或其他司法管辖区）		（委员会档案编号）		（美国国税局雇主识别号）
\n	\n
733 Concord Avenue Cambridge, MA		\n		02138
（主要行政办公室地址）		\n		（邮政编码）

注册人电话号码（含区号）：(617) 949-2900

如果本 Form 8-K 文件旨在同时满足注册人根据以下任何规定承担的申报义务，请勾选下方相应方框（参见下方一般说明 A.2）：

\n\n\n

☐	根据《证券法》（17 CFR 230.425）第425条进行的书面通信

\n\n\n

☐	根据《交易法》（17 CFR 240.14a-12)）第 14a-12 条提供的征求材料

\n\n\n

☐	根据《交易法》（17 CFR 240.14d-2(b))）第 14d-2(b) 条进行的要约开始前通信

\n\n\n

☐	根据《交易法》（17 CFR 240.13e-4(c))）第 13e-4(c) 条进行的要约开始前通信

请勾选以表明注册人是否为《1933年证券法》第405条（本章§230.405）或《1934年证券交易法》第 12b-2 条（§240.12b-2）所定义的新兴成长型公司。

新兴成长型公司 ☐

如果属于新兴成长型公司，请勾选以表明注册人是否选择不使用《交易法》第13(a)条规定的延长过渡期，以遵守任何新的或修订后的财务会计准则。 ☐

根据该法第12(b)条注册的证券：

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

各类别名称

交易

代码

上市交易所名称

上市交易所

普通股，每股面值 $0.001

WVE

纳斯达克全球市场

\n\n\n

第 2.02项

经营业绩和财务状况。

2026年10月27日，Wave Life Sciences, Inc.公布了截至2026年9月30日季度的财务业绩。与该公告相关发布的新闻稿全文作为附件99.1随本 Form 8-K 当前报告一并提供，并通过引用纳入本文。

本第2.02项中的信息仅为提供，不应视为根据经修订的《1934年证券交易法》（“《交易法》”）第 18条“提交”，亦不受该条规定的责任约束；除非相关文件明确具体引用，否则该信息也不应视为通过引用纳入根据经修订的《1933年证券法》或《交易法》提交的任何注册声明或其他文件.

\n\n\n

第 9.01项

财务报表和附件。

(d) 附件

以下与第2.02项有关的附件仅供提供，不作提交：

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n
附件编号		说明
\n
99.1		Wave Life Sciences, Inc.于2026年10月27日发布的新闻稿
\n
104		封面交互式数据文件（嵌入 Inline XBRL 文件中）

签名

根据《1934年证券交易法》的要求，注册人已正式授权下述签署人代表其签署本报告。

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n
WAVE LIFE SCIENCES, INC.
\n
签署人：		/s/ Kyle Moran, CFA
\n		Kyle Moran, CFA
\n		首席财务官

日期：2026年10月27日

","original","zhKind","translation","complete","WVE","公司与财报","财报","aihot","/items/gv83tere3h9ug7v32ezu06dv3","https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/0001193125-26-432690-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1793404800&sig=9a7f389fcbee500f","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1793404800&sig=a2cbe235c7e6557c 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1793404800&sig=a86146f288f5a814 96w","changelogVersion","2026-10-01T08:00"]